SEC Form SC 13G filed by Neuronetics Inc.

$STIM
Medical/Dental Instruments
Health Care
Get the next $STIM alert in real time by email
SC 13G 1 stim_13gv3.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

 

(Amendment No.)*

 

 

Neuronetics, Inc.
(Name of Issuer)
 
Common Stock, $0.01 par value
(Title of Class of Securities)
 
64131A105
(CUSIP Number)
 
June 18, 2024
(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

o Rule 13d-1(b)
x Rule 13d-1(c)
o Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 64131A10513GPage 1 of 9 Pages

 

 

 

 

1.

 

NAME OF REPORTING PERSONS

Kent Lake Partners LP

 

 

2.

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)     o

(b)     o

 

 

3.

 

SEC USE ONLY

 

 

4.

 

 

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

 

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

 

5.

 

SOLE VOTING POWER

0

 

 

6.

 

SHARED VOTING POWER

1,500,000

 

 

7.

 

SOLE DISPOSITIVE POWER

0

 

 

8.

 

 

SHARED DISPOSITIVE POWER

1,500,000

 

 

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,500,000

 

 

10.

 

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

(SEE INSTRUCTIONS)

o

 

 

11.

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.0% (See Note 1)

 

 

12.

 

 

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

PN

 

       

(1)Based on 29,997,563 outstanding shares of Common Stock (as defined in Item 2(d) below) as of May 3, 2024 represented in the Issuer's 10-Q filed with the Securities and Exchange Commission ("SEC") on May 7, 2024.

 

 

CUSIP No. 64131A10513GPage 2 of 9 Pages

 

 

 

1.

 

NAME OF REPORTING PERSONS

Kent Lake Capital LLC

 

 

2.

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)     o

(b)     o

 

 

3.

 

SEC USE ONLY

 

 

4.

 

 

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

 

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

 

5.

 

SOLE VOTING POWER

0

 

 

6.

 

SHARED VOTING POWER

1,500,000 (See Note 3)

 

 

7.

 

SOLE DISPOSITIVE POWER

0

 

 

8.

 

 

SHARED DISPOSITIVE POWER

1,500,000 (See Note 3)

 

 

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,500,000 (See Note 3)

 

 

10.

 

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

(SEE INSTRUCTIONS)

o

 

 

11.

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.0% (See Note 2)

 

 

12.

 

 

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

IA, HC

 

       

(2)See Note (1) Above.

 

(3)Pursuant to Rule 13d-4 under the Securities Exchange Act of 1934, as amended, Kent Lake Capital LLC expressly disclaims beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that Kent Lake Capital LLC is the beneficial owner of any of the securities reported herein.

CUSIP No. 64131A10513GPage 3 of 9 Pages

 

 

 

1.

 

NAME OF REPORTING PERSONS

Benjamin Natter

 

 

2.

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)     o

(b)     o

 

 

3.

 

SEC USE ONLY

 

 

4.

 

 

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

 

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

 

5.

 

SOLE VOTING POWER

0

 

 

6.

 

SHARED VOTING POWER

1,500,000

 

 

7.

 

SOLE DISPOSITIVE POWER

0

 

 

8.

 

 

SHARED DISPOSITIVE POWER

1,500,000

 

 

 

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,500,000

 

 

10.

 

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

(SEE INSTRUCTIONS)

o

 

 

11.

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.0% (See Note 4)

 

 

12.

 

 

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

IN, HC

 

       

(4) See Note (1) Above.

 

CUSIP No. 64131A10513GPage 4 of 9 Pages

 

Item 1(a).Name of Issuer:

 

Neuronetics, Inc. (the “Issuer”)

 

Item 1(b).Address of Issuer’s Principal Executive Offices:

 

3222 Phoenixville Pike

Malvern, PA 19355

 

Item 2(a).Name of Persons Filing:

 

This statement is filed by the entities and persons listed below, who are collectively referred to herein as "Reporting Persons", with respect to the shares of Common Stock (as defined in Item 2(d) below) of the Company:

 

(i)Kent Lake Partners LP

 

(ii)Kent Lake Capital LLC

 

(iii)Benjamin Natter

 

Item 2(b).Address of Principal Business Office or, if none, Residence:

 

(i)Kent Lake Partners LP

c/o Kent Lake Capital LLC

300 East 2nd Street, Suite 1510, #1033

Reno, NV 89501

 

(ii)Kent Lake Capital LLC

300 East 2nd Street, Suite 1510, #1033

Reno, NV 89501

 

(iii)Benjamin Natter

c/o Kent Lake Capital LLC

300 East 2nd Street, Suite 1510, #1033

Reno, NV 89501

 

Item 2(c).Citizenship:

 

(i)Kent Lake Partners LP – DE

 

(ii)Kent Lake Capital LLC – DE

 

(iii)Benjamin Natter – USA

 

Item 2(d).Title of Class of Securities:

 

Common Stock, $0.01 par value per share (“Common Stock”)

 

Item 2(e).CUSIP Number:

 

64131A105

 

Item 3.If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

 

Not Applicable.

 

CUSIP No. 64131A105 13G Page 5 of 9 Pages

 

 

 

Item 4.Ownership

 

(i)Kent Lake Partners LP

 

(a)Amount beneficially owned: 1,500,000 (See Note 5)

 

(b)Percent of class: 5.0% (See Note 6)

 

(c)Number of shares as to which the person has:

 

(i)Sole power to vote or to direct the vote: 0

 

(ii)Shared power to vote or to direct the vote: 1,500,000 (see Note 5)

 

(iii)Sole power to dispose or to direct the disposition of: 0

 

(iv)Shared power to dispose or to direct the disposition of: 1,500,000 (See Note 5)

 

(ii)Kent Lake Capital LLC

 

(a)Amount beneficially owned: 1,500,000 (See Note 5)

 

(b)Percent of class: 5.0% (See Note 6)

 

(c)Number of shares as to which the person has:

 

(i)Sole power to vote or to direct the vote: 0

 

(ii)Shared power to vote or to direct the vote: 1,500,000 (see Note 5)

 

(iii)Sole power to dispose or to direct the disposition of: 0

 

(iv)Shared power to dispose or to direct the disposition of: 1,500,000 (See Note 5)

 

(iii)Benjamin Natter

 

(a)Amount beneficially owned: 1,500,000 (See Note 5)

 

(b)Percent of class: 5.0% (See Note 6)

 

(c)Number of shares as to which the person has:

 

(i)Sole power to vote or to direct the vote: 0

 

(ii)Shared power to vote or to direct the vote: 1,500,000 (See Note 5)

 

(iii)Sole power to dispose or to direct the disposition of: 0

 

(iv)Shared power to dispose or to direct the disposition of: 1,500,000 (See Note 5)

 

CUSIP No. 64131A105 13G Page 6 of 9 Pages

 

 

Note 5:

 

Kent Lake Capital LLC is an investment advisor that is registered under the Investment Advisors Act of 1940. Kent Lake Capital LLC may be deemed to be the beneficial owner of all shares of Common Stock held by Kent Lake Partners LP ("the Fund"). Mr. Benjamin Natter, as Managing Member of Kent Lake Capital LLC, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owner of all shares of Common Stock held by the Fund. Pursuant to Rule 13d-4 under the Securities Exchange Act of 1934, as amended, Kent Lake Capital LLC and Mr. Natter expressly disclaim beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that Kent Lake Capital LLC or Mr. Natter are the beneficial owner of any of the securities reported herein.

 

Note 6:

 

Based on 29,997,563 outstanding shares of Common Stock as of May 3, 2024 represented in the Issuer's 10-Q filed with the SEC on May 7, 2024.

 

Item 5.Ownership of Five Percent or Less of a Class:

 

Not Applicable.

  

Item 6.Ownership of More Than Five Percent on Behalf of Another Person:

 

Not Applicable.

  

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

 

See Note 5 above.

 

Item 8.Identification and Classification of Members of the Group:

 

Not Applicable.

  

Item 9.Notice of Dissolution of Group:

 

Not Applicable.

  

CUSIP No. 64131A105 13G Page 7 of 9 Pages

 

 

Item 10.Certifications:

 

Each of the Reporting Persons makes the following certification:

 

By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

 

 

Date: June 28, 2024

 

 

 

KENT LAKE PARTNERS LP

By: Kent Lake GP LLC, its General Partner

By: /s/ Benjamin Natter

Name: Benjamin Natter

Title: Managing Member

 

 

KENT LAKE CAPITAL LLC

By: /s/ Benjamin Natter

Name: Benjamin Natter

Title: Managing Member

 

 

BENJAMIN NATTER

By: /s/ Benjamin Natter

 

 

CUSIP No. 64131A105 13G Page 8 of 9 Pages

 

 

EXHIBIT A

 

Joint Filing Agreement Pursuant to Rule 13d-1

 

This agreement is made pursuant to Rule 13d-l(k)(1) under the Securities Exchange Act of 1934, as amended (the "Act") by and among the parties listed below, each referenced to herein as a "Joint Filer". The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the rules thereunder may be filed on each of his, her or its behalf on Schedule 13G or Schedule 13D, as appropriate, and that said joint filing may thereafter be amended by further joint filings. The Joint Filers state that they each satisfy the requirements for making a joint filing under Rule 13d-1(k).

 

 

Dated:  June 28, 2024
     

KENT LAKE PARTNERS LP

By: Kent Lake GP LLC, its General Partner

By: /s/ Benjamin Natter

Name: Benjamin Natter

Title: Managing Member

 

 

KENT LAKE CAPITAL LLC

By: /s/ Benjamin Natter

Name: Benjamin Natter

Title: Managing Member

 

 

BENJAMIN NATTER

By: /s/ Benjamin Natter

 

 

 

 

CUSIP No. 64131A105 13G Page 9 of 9 Pages

Get the next $STIM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$STIM

DatePrice TargetRatingAnalyst
8/13/2024Outperform → Mkt Perform
William Blair
10/14/2021$18.00 → $12.00Market Outperform
JMP Securities
10/13/2021Outperform → Mkt Perform
William Blair
10/13/2021Buy → Neutral
BTIG
More analyst ratings

$STIM
Press Releases

Fastest customizable press release news feed in the world

See more
  • Neuronetics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

    MALVERN, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the fourth quarter and full year of 2024. Fourth Quarter 2024 Highlights Acquired Greenbrook TMS on December 9, 2024Received an incremental $10 million in funding from Perceptive AdvisorsFourth quarter 2024 revenue of $22.5 million, a 11% increase as compared to the fourth quarter 2023U

    $STIM
    Medical/Dental Instruments
    Health Care
  • Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 24,750 shares of the Company's common stock (RSUs) to three new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as material inducements to their respective employment with the Company. Three of the RSU grants vests ratably i

    $STIM
    Medical/Dental Instruments
    Health Care
  • Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release fourth quarter 2024 financial and operating results prior to market open on Tuesday, March 4, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/a3eb5opb. To listen to the conference call on your telephone, participants may register fo

    $STIM
    Medical/Dental Instruments
    Health Care

$STIM
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$STIM
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$STIM
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$STIM
SEC Filings

See more

$STIM
Leadership Updates

Live Leadership Updates

See more
  • Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis Medical

    Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja

    $STIM
    $ABMD
    Medical/Dental Instruments
    Health Care
  • Neuronetics Announces Appointment of Joseph H. Capper to its Board of Directors

    MALVERN, Pa., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today announced the appointment of Joseph H. Capper to its Board of Directors and as a member of the Audit Committee effective January 1, 2023. "Joe is well known and extremely well regarded in the med-tech community for his ability to advance company goals," said Rob Cascella, Chairman of the Board of Neuronetics. "His depth of experience with public companies and his passion for innovative medical technologies will

    $BEAT
    $STIM
    Medical/Dental Instruments
    Health Care
  • IMPULSE DYNAMICS APPOINTS FIVE NEW BOARD MEMBERS

    MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders.  "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics.  "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo

    $BEAT
    $GMED
    $GTHX
    $HOLX
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Electronics

$STIM
Financials

Live finance-specific insights

See more
  • Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release fourth quarter 2024 financial and operating results prior to market open on Tuesday, March 4, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/a3eb5opb. To listen to the conference call on your telephone, participants may register fo

    $STIM
    Medical/Dental Instruments
    Health Care
  • CORRECTION—Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results

    MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- In a release issued earlier today under the same headline by Neuronetics, Inc. (NASDAQ:STIM), please note that in the second paragraph of the "Stockholders Approve Acquisition of Greenbrook TMS" section, it should say that the Company expects to achieve cash flow breakeven by the third quarter of 2025, not the second. The corrected release follows: Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and ope

    $STIM
    Medical/Dental Instruments
    Health Care
  • Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results

    MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the third quarter of 2024. Third Quarter 2024 Highlights Third quarter 2024 revenue of $18.5 million, a 4% increase as compared to the third quarter 2023U.S. NeuroStar Advanced Therapy system revenue of $4.1 million in the quarter, representing 48 systemsU.S. treatment session revenue increased by 2% versus the third quarter of

    $STIM
    Medical/Dental Instruments
    Health Care

$STIM
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more